Clinical Validation of microRNA Binding Site Mutations in Cancer Risk, Prevention, and Treatment

What this Trial Is About

Researchers are studying mutations in microRNA binding sites, including the KRAS-variant, which may increase the risk of cancer, endometriosis, infertility, and affect tumor behavior and treatment response. The study aims to better understand how these genetic changes relate to health conditions like cancer and autoimmunity. Participants who may carry these mutations will be enrolled to help validate their role in disease risk, prevention, and treatment. Participants will provide saliva samples for testing to detect the KRAS-variant and other related mutations. With permission, extra DNA will be stored for further research. Throughout the study, participants will answer lifestyle questionnaires to help researchers see how different factors influence cancer risk in people with these genetic changes. During the study, researchers will measure how common the KRAS-variant is among certain groups, such as breast cancer patients without BRCA mutations, and compare outcomes between those with and without the variant. Participants may receive their test results through their physician after the study. The study involves ongoing data collection and monitoring over about a year to understand the impact of these mutations on health.

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment